OPKO Health, Inc.
OPK · NASDAQ
Financial statements
Annual and quarterly income, balance-sheet, cash-flow and key-statistics data.
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2022 FY | 1.00B | 288.22M | -226.25M | -328.41M | -0.46 |
| 2023 FY | 863.50M | 318.13M | -157.02M | -188.86M | -0.25 |
| 2024 FY | 713.14M | 311.03M | -152.07M | -53.22M | -0.08 |
| 2025 FY | 606.88M | 128.05M | -218.99M | -225.68M | -0.30 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2022 FY | 2.17B | 605.61M | 153.19M | 305.55M | 1.56B |
| 2023 FY | 2.01B | 622.48M | 95.88M | 326.56M | 1.39B |
| 2024 FY | 2.20B | 834.76M | 431.94M | 504.44M | 1.37B |
| 2025 FY | 1.93B | 663.99M | 369.07M | 433.60M | 1.27B |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2022 FY | -95.19M | -24.58M | -119.77M | — | 18.48M |
| 2023 FY | -28.20M | -16.28M | -44.47M | — | -57.31M |
| 2024 FY | -183.49M | -25.01M | -208.50M | — | 349.73M |
| 2025 FY | -178.54M | -12.28M | -190.82M | — | -62.87M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2022 FY | 898.83M | 1.05B | — | — | — |
| 2023 FY | 1.14B | 1.37B | — | — | — |
| 2024 FY | 1.02B | 1.09B | — | — | — |
| 2025 FY | 946.43M | 1.01B | — | — | — |
| 2026-12-31 | — | — | — | — | — |
| 2027-12-31 | — | — | — | — | — |
| 2028-12-31 | — | — | — | — | — |
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 Q2 | 156.81M | 29.96M | -59.98M | -148.44M | -0.19 |
| 2025 Q3 | 151.67M | 30.36M | -53.52M | 21.63M | 0.03 |
| 2025 Q4 | 148.45M | 44.97M | -38.32M | -31.26M | -0.04 |
| 2026 Q1 | 124.20M | 26.79M | -51.02M | -54.85M | -0.07 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2025 Q2 | 1.97B | 676.09M | 271.72M | 395.74M | 1.30B |
| 2025 Q3 | 2.00B | 690.02M | 415.20M | 395.42M | 1.31B |
| 2025 Q4 | 1.93B | 663.99M | 369.07M | 433.60M | 1.27B |
| 2026 Q1 | 1.86B | 652.19M | 341.88M | 396.93M | 1.20B |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2025 Q2 | -83.42M | -3.28M | -86.70M | — | -164.28M |
| 2025 Q3 | -34.65M | -3.14M | -37.78M | — | 143.48M |
| 2025 Q4 | -25.92M | -2.67M | -28.59M | — | -46.13M |
| 2026 Q1 | -19.31M | -1.83M | -21.14M | — | -27.18M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2025 Q2 | 1.04B | 1.16B | — | — | — |
| 2025 Q3 | 1.20B | 1.18B | — | — | — |
| 2025 Q4 | 964.55M | 1.03B | — | — | — |
| 2026 Q1 | 865.12M | 920.17M | — | — | — |
| 2026-06-30 | — | — | — | — | — |
| 2026-09-30 | — | — | — | — | — |
| 2026-12-31 | — | — | — | — | — |